Inhibrx Biosciences (INBX) Non-Current Assets (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Non-Current Assets data on file, last reported at $13.6 million in Q4 2025.

• Non-Current Assets for Q4 2025 came in at $13.6 million, down 33.01% year-over-year; the trailing twelve-month figure through Dec 2025 was $67.1 million (up 4.22% YoY), and the FY2025 annual result was $13.6 million, down 33.01% from the prior year.
• Non-Current Assets fell to $13.6 million in Q4 2025 per INBX's latest filing, from $16.0 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $20.4 million in Q4 2024 and troughed at $12.5 million in Q4 2023.
• A 3-year average of $16.4 million and a median of $16.2 million in 2024 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2024 and 2025: Non-Current Assets jumped 62.5% in 2024, then tumbled 33.01% in 2025.
• A 3-year view of Non-Current Assets shows it stood at $12.5 million in 2023, then soared by 62.5% to $20.4 million in 2024, then plunged by 33.01% to $13.6 million in 2025.
• Business Quant data shows INBX's Non-Current Assets at $13.6 million in Q4 2025, $16.0 million in Q3 2025, and $18.2 million in Q2 2025.